TAIPEI, Dec. 30, 2024 /PRNewswire/ -- In the rapidly evolving tech landscape, smart wearable devices enriched with artificial intelligence (AI) and augmented reality (AR) are redefining the boundaries of innovation. Leading the charge, members of the AI on Chip Industrial Cooperation Strategic Alliance, including Jorjin, Singular Wings Medical, and SoundLand, are demonstrating formidable expertise by leveraging their distinctive technological capabilities.
Jorjin has made significant strides by integrating AR glasses with AI to facilitate educational training and standard operating procedure (SOP) guidance, helping workers quickly master critical skills. Additionally, the company has launched the MetaSpace AR interaction platform, which enhances visitor engagement through personalized commentary and interactive experiences at immersive exhibitions and educational settings, bringing AR closer to daily life.
Singular Wings Medical is revolutionizing blood sugar monitoring with its innovative use of wearable electrocardiograms (ECG) sensors. The company's technology analyzes blood sugar changes without the need for blood sampling or skin punctures, addressing key issues of invasiveness and data discontinuity. By employing AI algorithms and extensive clinical data, the company precisely monitors blood sugar levels, offering personalized health management solutions that boost medical efficiency and cut costs.
SoundLand, a pioneer in sound processing, has unveiled its latest electronic and patch-type stethoscopes designed for remote transmission of cardiopulmonary sounds. These cutting-edge devices support telemedicine and educational training, facilitating ongoing monitoring of vital signs and enhancing the convenience of patient care.
Together, Jorjin, Singular Wings Medical, and SoundLand are driving industrial innovation, highlighting the vast potential of Taiwanese firms in the global AI and smart wearables market.
For more information on Taiwan's premier manufacturers, please contact service@ai-on-chip-b2bmatch.org.tw
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Taiwanese Companies Lead Innovation in AI-Powered Smart Wearables
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
